BioClavis is a Glasgow-based personalised diagnostics spinout of US-based BioSpyder Technologies.
We’re enabling the full promise and clinical utility of ‘omic testing to deliver cost-effective care for individual patients in coordination with and context of the practical realities in today’s healthcare systems. BioClavis leverages the proprietary TempO-Seq® transcriptomic/genomic platform technology (developed by BioSpyder), capable of efficiently analysing large cohorts with customisable biomarker panels of tens to thousands of genes, quickly and inexpensively. It has critical usability features, controls, and does not require specialised instrumentation, ideal for expansion into the clinic. These strengths–in concert with centralised patient samples, clinical research partners, and economic decision making–allow accelerating content discovery, product development and adoption of a new generation of cost-disruptive precision medicine testing worldwide.